/BMXMF
BMXMF Stock - bioMérieux S.A.
Healthcare|Medical - Diagnostics & ResearchOTC
$131.00+0.00%
+$0.00 (+0.00%) • Jan 13
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.53
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $144.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BMXMF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$129.69 – $132.31
TARGET (TP)$150.65
STOP LOSS$120.52
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.68
52W High$152.00
52W Low$110.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.98B | $3.67B | $3.59B | $3.38B | $3.12B |
| Gross Profit | $2.22B | $2.06B | $2.01B | $2.00B | $1.75B |
| Gross Margin | 55.7% | 56.0% | 56.0% | 59.3% | 56.2% |
| Operating Income | $588.80M | $439.00M | $587.20M | $784.30M | $552.80M |
| Net Income | $432.20M | $357.60M | $452.40M | $601.10M | $404.40M |
| Net Margin | 10.9% | 9.7% | 12.6% | 17.8% | 13.0% |
| EPS | $3.67 | $3.03 | $3.84 | $5.08 | $3.42 |
Company Overview
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BMXMFBeat Rate
43%
Last 7 quarters
Avg Surprise
+8.2%
EPS vs Estimate
Beats / Misses
3/4
Last 12 quarters
Latest EPS
$1.59
Q2 2025
EPS Surprise History
Q4 21
+61.3%
$3.08vs$1.91
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q4 23
No data
Q2 24
No data
Q4 24
-15.2%
$1.89vs$2.23
Q2 25
-37.6%
$1.59vs$2.55
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 5, 2026 | — | — | — | — |
Q2 2025 | Jun 30, 2025 | $2.55 | $1.59 | -37.6% | ✗ MISS |
Q4 2024 | Dec 31, 2024 | $2.23 | $1.89 | -15.2% | ✗ MISS |
Q2 2024 | Jun 29, 2024 | — | $1.95 | — | — |
Q4 2023 | Dec 30, 2023 | — | $1.81 | — | — |
Q2 2023 | Jun 30, 2023 | — | $1.49 | — | — |
Q4 2022 | Dec 31, 2022 | — | $2.04 | — | — |
Q2 2022 | Jun 30, 2022 | — | $2.01 | — | — |
Q4 2021 | Dec 31, 2021 | $1.91 | $3.08 | +61.3% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | $2.22 | $2.77 | +24.8% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | $1.70 | $2.39 | +40.6% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | $1.81 | $1.64 | -9.4% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | $1.36 | $1.27 | -6.6% | ✗ MISS |
Q2 2019 | Jun 30, 2019 | — | $1.34 | — | — |
Q4 2018 | Dec 31, 2018 | — | $1.24 | — | — |
Q2 2018 | Jun 30, 2018 | — | $1.32 | — | — |
Q4 2017 | Dec 31, 2017 | — | $1.35 | — | — |
Q2 2017 | Jun 30, 2017 | — | $0.98 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.83 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.80 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BMXMF
What is BMXMF's current stock price?
bioMérieux S.A. (BMXMF) is currently trading at $131.00 per share. The stock has moved +0.00% today.
What is the analyst price target for BMXMF?
No analyst price targets are currently available for this stock.
What sector is bioMérieux S.A. in?
bioMérieux S.A. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the OTC exchange.
What is BMXMF's market cap?
bioMérieux S.A. has a market capitalization of $15.47 billion, making it a large-cap company.
Does BMXMF pay dividends?
No, bioMérieux S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorA
Agilent Technologies, Inc.
$146.32
Mkt Cap: $41.5B
APDN
Applied DNA Sciences, Inc.
$5.62
Mkt Cap: $0.0B
CDNA
CareDx, Inc
$20.19
Mkt Cap: $1.0B
CRL
Charles River Laboratories International, Inc.
$218.99
Mkt Cap: $10.8B
DHR
Danaher Corporation
$235.56
Mkt Cap: $168.8B
FONR
FONAR Corporation
$18.60
Mkt Cap: $0.1B
GH
Guardant Health, Inc.
$106.89
Mkt Cap: $13.3B
ICLR
ICON Public Limited Company
$183.29
Mkt Cap: $14.0B
ILMN
Illumina, Inc.
$146.99
Mkt Cap: $22.5B
IQV
IQVIA Holdings Inc.
$241.57
Mkt Cap: $41.1B
Explore stocks similar to BMXMF for comparison